AMENDMENT

Please replace presently pending claims 1-24 with the following claims 1-24:

1. A method of treating multiple sclerosis (MS), including the step of administering to an individual a pharmaceutically-effective amount of cpn10 and IFN-β

2. The method of claim 1, when used as a treatment to prevent relapse of MS.

3. (Amended) The method of claim 1, wherein IFN-β and cpn10 are administered together.

a1

4. (Amended) The method of claim 1, wherein IFN-β and cpn10 are administered separately.

5. The method of claim 3, wherein IFN-β and cpn10 are administered by injection.

6. The method of claim 4, wherein cpn10 is administered orally.

7. (Amended) The method of claim 4, wherein IFN-β is administered by injection.

a2

8. (Amended) The process of claim 1, wherein the pharmaceutically effective amount of cpn10 and IFN-β comprises 5-60 mg of cpn10..

9. The method of claim 8, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 10-30 mg of cpn10.

a3

10. (Amended) The method of claim 1, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 1-10 Million International Units (MIU) of IFN-β .

11. The method of claim 10, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 4-6 (MIU) of IFN-β.

12. A pharmaceutical composition for treating MS, said composition comprising a pharmaceutically-effective amount of cpn10 and IFN-β and a pharmaceutically-acceptable carrier or diluent.

13. The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 5-60 mg of cpn10.

14. The composition of claim 13, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 10-30 mg of cpn10.

15. The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 1-10 MIU of IFN-β.

16. The composition of claim 15, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 4-6 MIU of IFN-β.

17. A kit comprising a pharmaceutically-effective amount of cpn10 and IFN-βand a pharmaceutically-acceptable carrier or diluent.

18. The kit of claim 17, wherein said IFN-β is in dehydrated form, which in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

19. The kit of claim 18, wherein said cpn10 is in dehydrated form and in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

Q4 20. (Amended) The kit of claim 17, wherein said cpn10 is in tablet or capsule form.

21. The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 5-60 mg of cpn10.

22. The kit of claim 21, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 10-30 mg of cpn10.

23. The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 1-10 MIU of IFN-β.

24. The kit of claim 23, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 4-6 MIU of IFN-β.